Eventide Asset Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Eventide Asset Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-170,442	Closed	-$7.25M	–	133
2019 Q1	$7.25M	Buy	170,442 +105,715	+163%	+$2.4M	0.25%	81
2018 Q4	$942K	Hold	64,727	–	–	0.04%	119
2018 Q3	$4.53M	Hold	64,727	–	–	0.17%	100
2018 Q2	$4.8M	Hold	64,727	–	–	0.2%	95
2018 Q1	$6.16M	Hold	64,727	–	–	0.29%	85
2017 Q4	$8.36M	Buy	64,727 +64,353	+17,207%	+$6.03M	0.44%	65
2017 Q3	$25K	Buy	+374	New	+$30.5K	﹤0.01%	136
2014 Q4	–	Sell	-437	Closed	-$655K	–	109
2014 Q3	$655K	Hold	437	–	–	0.09%	99
2014 Q2	$599K	Hold	437	–	–	0.08%	101
2014 Q1	$607K	Hold	437	–	–	0.09%	97
2013 Q4	$435K	Buy	+437	New	+$452K	0.13%	89

Other funds holding VIRX

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Eventide Asset Management's VIRX Position: Q2 2019 in Review

Eventide Asset Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2019, closing a stake of 170,442 shares — an estimated $7.25M sold.

Eventide Asset Management first reported a position in VIRX in Q4 2013 and held it in 11 quarters. The position peaked at $8.36M in Q4 2017. 45 funds tracked by Wall St. Rank hold VIRX as of Q2 2019.

Eventide Asset Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Eventide Asset Management sold 170,442 Viracta Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $7.25M.
Eventide Asset Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2013 and held it in 11 quarters.
Eventide Asset Management's Viracta Therapeutics, Inc. Common Stock position peaked at $8.36M in Q4 2017.
45 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Eventide Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.